Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4963-4970

  Coppola, Domenico ^a   Nicosia, Santo V ^b   Doty, Andrea ^a   Sellers, Thomas A ^a   Lee, Ji Hyun ^a   Fulp, Jimmy ^a   Thompson, Zachary ^a   Galeb, Sanja ^a   McLaughlin, John ^c   Narod, Steven A ^d   Schildkraut, Joellen ^e   Pal, Tuya ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IHC; Immunohistochemistry; Mismatch repair; MLH1; MSH2; MSH6; Ovarian cancer

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CARCINOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872647664     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. American Cancer Society I. Cancer Facts & Figures 2007. [Internet]: American Cancer Society, Inc.; 2007 Available from: http://www.cancer.org/ docroots/STT/stt-0.asp.
2. Pal T, Permuth-Wey J and Sellers TA: A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer 113(4): 733-742, 2008.
3. Murphy MA and Wentzensen N: Frequency of mismatch repair deficiency in ovarian cancer: A systematic review. Int J Cancer 129(8): 1914-1922, 2011.
4. Lynch HT, Lynch PM, Lanspa SJ et al: Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76(1): 1-18, 2009.
5. Lynch PM. Current approaches in familial colorectal cancer: a clinical perspective. J Natl Compr Canc Netw 4(4): 421-430, 2006.
6. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al: Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27(28): 4793-4797, 2009.
7. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med J 11(1): 35-41, 2009.
8. Domanska K, Malander S, Masback A et al: Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. Int J Gynecol Cancer 17(4): 789-793, 2007.
9. Malander S, Rambech E, Kristoffersson U et al: The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 101(2): 238-243, 2006.
10. Rosen DG, Cai KQ, Luthra R et al: Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol 19(11): 1414-1420, 2006.
11. Ichikawa Y, Lemon SJ, Wang S et al: Microsatellite instability and expression of MLH1 and MSH2 in normal and malignant endometrial and ovarian epithelium in hereditary nonpolyposis colorectal cancer family members. Cancer Genet Cytogenet 112(1): 2-8, 1999.
12. Chiaravalli AM, Furlan D, Facco C et al: Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch 438(1): 39-48, 2001.
13. Ketabi Z, Bartuma K, Bernstein I et al: Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol 121(3): 462-465, 2011.
14. Sood AK, Holmes R, Hendrix MJ et al: Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer. Cancer Res 61(11): 4371-4374, 2001.
15. Pal T, Permuth-Wey J, Kumar A et al: Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res 14(21): 6847-6854, 2008.
16. Risch HA, McLaughlin JR, Cole DE et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68(3): 700-710, 2001.
17. Pal T, Permuth-Wey J, Betts JA et al: BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104(12): 2807-2816, 2005.
18. Wenham RM, Schildkraut JM, McLean K et al: Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res 9(12): 4396-4403, 2003.
19. Fedor HL and De Marzo AM: Practical methods for tissue microarray construction. Methods Mol Med 103: 89-101, 2005.
20. Jourdan F, Sebbagh N, Comperat E et al: Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443(2): 115-121, 2003.
21. Hecht JL, Kotsopoulos J, Gates MA et al : Validation of tissue microarray technology in ovarian cancer: results from the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 17(11): 3043-3050, 2008.
22. Rosen DG, Huang X, Deavers MT et al : Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17(7): 790-797, 2004.
23. Rosen B, Kwon J, Fung Kee Fung M et al: Systematic review of management options for women with a hereditary predisposition to ovarian cancer. Gynecol Oncol 93(2): 280-286, 2004.
24. Seidman JD, Horkayne-Szakaly I, Haiba M et al: The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23(1): 41-44, 2004.
25. Jacobs TW, Gown AM, Yaziji H et al: HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol 113(2): 251-258, 2000.
26. Wolff AC, Hammond ME, Schwartz JN et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1): 118-145, 2007.